KRMD — KORU Medical Systems Inc
NASDAQ · Health Care · Health Care
- Latest Close
- $3.96
- 30-Day Move
- -31.8%
- Market Cap
- $200M
- Shares Outstanding
- 46,370,000
- P/B Ratio
- 15.79
- ROE
- -15.5%
KORU Medical Systems Inc
A read-only Alphactor snapshot forKORU Medical Systems Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$3.96
30-Day Move
-31.8%
Market Cap
$200M
Shares Outstanding
46,370,000
P/B Ratio
15.79
ROE
-15.5%
$3.96
-31.8%last 90 delayed daily bars
90D High
$6.61
90D Low
$3.92
Avg Volume
183,269
Gross margin is running at 62.3%, which gives a quick read on operating quality before you open the full model.
Net margin is -6.4%, useful for comparing KRMD against peers in Health Care.
KRMD is down 31.8% over the last 30 trading days shown on this page.
Latest operating income is $-547,104, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$2.43
Rule of 40
21.0%
Dark Pool Short %
21.7%
Latest Close
$3.96
30-Day Move
-31.8%
Market Cap
$200M
Shares Outstanding
46,370,000
P/B Ratio
15.79
ROE
-15.5%
ROA
-9.3%
Gross Margin
62.3%
Operating Margin
-7.2%
Net Margin
-6.4%
Debt / Equity
0.01
Current Ratio
2.44
Latest Revenue
$11M
Revenue
$11M
Gross Profit
$7M
Operating Income
$-547,104
Net Income
$-486,856
Gross Margin
6226.0%
Net Margin
-641.0%
Current Ratio
2.44
Debt / Equity
0.01
Fair Value
$2.43
Upside / Downside
-38.6%
Signal
Overvalued
Implied Growth
53.8%
DCF
$0.31
EV/Rev
$4.55
Growth Assumption
13.8%
Discount Rate
10.5%
Terminal Growth
2.0%
Base FCF
$462,405
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Very aggressive growth priced in
Altman Z
10.80
Safe
Piotroski
6
Moderate (4-6)
Cash Conversion
-0.18x
Rule of 40
21.0%
Concerning
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $28M | $-11M | $-9M | $-8M |
| 2023-12-31 | $29M | $-10M | $-14M | $-6M |
| 2024-12-31 | $34M | $-6M | $-6M | $-2M |
| 2025-12-31 | $41M | $-3M | $-3M | $-494,085 |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-01 | French Donna | A | 3,472 | $4.32 |
| 2026-04-01 | WHOLIHAN EDWARD | A | 3,472 | $4.32 |
| 2026-04-01 | Matin Shahriar | A | 3,472 | $4.32 |
| 2026-04-01 | CASCELLA ROBERT | A | 3,472 | $4.32 |
| 2026-04-01 | FLETCHER R JOHN | A | 5,208 | $4.32 |
| 2026-03-31 | Horton Capital Partners, LLC | A | 3,472 | $0.00 |
| 2026-03-31 | Horton Capital Partners, LLC | A | 3,472 | $0.00 |
| 2026-03-17 | KALBERMATTEN ADAM R | A | 67,779 | $0.00 |
Qube Research & Technologies
Filed 2025-08-14
--
--
Vanguard Group
Filed 2026-01-29
$13M
+2.9%
Geode Capital Management
Filed 2026-02-09
$6M
+1.6%
BlackRock
Filed 2024-05-10
$4M
--
Northern Trust
Filed 2026-02-17
$2M
-8.5%
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.